{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:00:46Z","timestamp":1791813646989,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009242","name":"DGOS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.autrev.2023.103314","type":"journal-article","created":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T18:45:04Z","timestamp":1678646704000},"page":"103314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Differentially expressed genes in systemic sclerosis: Towards predictive medicine with new molecular tools for clinicians"],"prefix":"10.1016","volume":"22","author":[{"given":"Shiri","family":"Keret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Rimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Lansiaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lescoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Milman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Farge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103314_bb0005","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR scleroderma trials and research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0010","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2023.103314_bb0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/ITT.S82037","article-title":"Current perspectives on the immunopathogenesis of systemic sclerosis","volume":"2016","author":"Fuschiotti","year":"2016","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.autrev.2023.103314_bb0020","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2665-9913(19)30038-4","article-title":"The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder","volume":"1","author":"Lescoat","year":"2019","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.autrev.2023.103314_bb0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103314_bb0030","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103314_bb0035","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.autrev.2023.103314_bb0045","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/ard.2010.144360","article-title":"Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres","volume":"70","author":"Fransen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0050","first-page":"1630","article-title":"Current status of outcome measure development for clinical trials in systemic sclerosis","volume":"30","author":"Merkel","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103314_bb0055","series-title":"Scleroderma: From pathogenesis to comprehensive management","first-page":"657","article-title":"Molecular stratification by gene expression as a paradigm for precision medicine in systemic sclerosis","author":"Hinchcliff","year":"2017"},{"key":"10.1016\/j.autrev.2023.103314_bb0060","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0065","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"10.1016\/j.autrev.2023.103314_bb0070","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ng1038","article-title":"Molecular portraits and the family tree of cancer","volume":"32","author":"Chung","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2023.103314_bb0075","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.4103\/0975-7406.100283","article-title":"Microarray and its applications","volume":"4","author":"Govindarajan","year":"2012","journal-title":"J Pharm Bioallied Sci"},{"key":"10.1016\/j.autrev.2023.103314_bb0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00018-009-0180-6","article-title":"RNA-seq: from technology to biology","volume":"67","author":"Marguerat","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.autrev.2023.103314_bb0085","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1101\/gr.079558.108","article-title":"RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays","volume":"18","author":"Marioni","year":"2008","journal-title":"Genome Res"},{"key":"10.1016\/j.autrev.2023.103314_bb0090","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2119\/2006-00107.Trevino","article-title":"DNA microarrays: a powerful genomic tool for biomedical and clinical research","volume":"13","author":"Trevino","year":"2007","journal-title":"Mol Med"},{"key":"10.1016\/j.autrev.2023.103314_bb0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ygeno.2017.08.007","article-title":"How many differentially expressed genes: a perspective from the comparison of genotypic and phenotypic distances","volume":"110","author":"Zhao","year":"2018","journal-title":"Genomics"},{"key":"10.1016\/j.autrev.2023.103314_bb0100","article-title":"Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells","volume":"9","author":"Zhao","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2023.103314_bb0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13062-015-0077-2","article-title":"Microarray experiments and factors which affect their reliability","volume":"10","author":"Jaksik","year":"2015","journal-title":"Biol Direct"},{"key":"10.1016\/j.autrev.2023.103314_bb0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/bib\/bbs046","article-title":"A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis","volume":"14","author":"Dillies","year":"2013","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.autrev.2023.103314_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pbi.2008.11.004","article-title":"Next is now: new technologies for sequencing of genomes, transcriptomes, and beyond","volume":"12","author":"Lister","year":"2009","journal-title":"Curr Opin Plant Biol"},{"key":"10.1016\/j.autrev.2023.103314_bb0120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41576-019-0150-2","article-title":"RNA sequencing: the teenage years","volume":"20","author":"Stark","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.autrev.2023.103314_bb0125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.12659\/MSMBR.892101","article-title":"Comparing bioinformatic gene expression profiling methods: microarray and RNA-Seq","volume":"20","author":"Mantione","year":"2014","journal-title":"Med Sci Monit Basic Res"},{"key":"10.1016\/j.autrev.2023.103314_bb0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1471-2164-10-161","article-title":"Estimating accuracy of RNA-Seq and microarrays with proteomics","volume":"10","author":"Fu","year":"2009","journal-title":"BMC Genomics"},{"key":"10.1016\/j.autrev.2023.103314_bb0135","article-title":"Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms","volume":"36","author":"PAC","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.autrev.2023.103314_bb0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13059-015-0694-1","article-title":"Comparison of RNA-seq and microarray-based models for clinical endpoint prediction","volume":"16","author":"Zhang","year":"2015","journal-title":"Genome Biol"},{"key":"10.1016\/j.autrev.2023.103314_bb0145","series-title":"Proceedings of 3rd International Conference on Document Analysis and Recognition","article-title":"Random decision forests","volume":"vol. 1","author":"Ho","year":"1995"},{"key":"10.1016\/j.autrev.2023.103314_bb0150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1023\/A:1022627411411","article-title":"Support-vector networks","volume":"20","author":"Cortes","year":"1995","journal-title":"Mach Learn"},{"key":"10.1016\/j.autrev.2023.103314_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.autrev.2023.103314_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/05bed72c-c6f6-4685-a732-02c78e5f66c2","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2023.103314_bb0165","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and cell type-specific gene expression patterns in scleroderma skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2023.103314_bb0170","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1002\/art.39289","article-title":"Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.autrev.2023.103314_bb0175","article-title":"Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time","author":"Skaug","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0180","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13075-017-1360-7","article-title":"Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature","volume":"19","author":"Derrett-Smith","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103314_bb0190","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/annrheumdis-2020-217116","article-title":"Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients","volume":"79","author":"Beretta","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0195","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/art.39287","article-title":"A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"67","author":"Rice","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103314_bb0200","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kei244","article-title":"Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients","volume":"45","author":"Tan","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103314_bb0205","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.22382","article-title":"A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll-like receptor agonists","volume":"56","author":"York","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103314_bb0210","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/art.27224","article-title":"Systemic sclerosis and lupus: points in an interferon-mediated continuum","volume":"62","author":"Assassi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103314_bb0215","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/art.30318","article-title":"Interferon and alternative activation of monocyte\/macrophages in systemic sclerosis-associated pulmonary arterial hypertension","volume":"63","author":"Christmann","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103314_bb0220","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.21894","article-title":"Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts","volume":"54","author":"Gardner","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103314_bb0225","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/jid.2011.472","article-title":"Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies","volume":"132","author":"Pendergrass","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2023.103314_bb0230","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/art.40898","article-title":"A machine learning classifier for assigning individual patients with systemic sclerosis to intrinsic molecular subsets","volume":"71","author":"Franks","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103314_bb0235","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2023.103314_bb0240","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13075-015-0695-1","article-title":"Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures","volume":"17","author":"Taroni","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103314_bb0245","first-page":"keac344","article-title":"A genomic Meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis","author":"Franks","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2023.103314_bb0250","first-page":"1","article-title":"Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity","author":"Lofgren","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2023.103314_bb0255","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2023.103314_bb0260","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/art.40455","article-title":"Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"70","author":"Stifano","year":"2018","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.autrev.2023.103314_bb0265","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1016\/S2665-9913(20)30237-X","article-title":"Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial","volume":"2","author":"Chung","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2023.103314_bb0270","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.autrev.2023.103314_bb0275","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/art.24221","article-title":"Molecular framework for response to imatinib mesylate in systemic sclerosis","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103314_bb0280","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.autrev.2023.103314_bb0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-54490-3_2","article-title":"Dasatinib","volume":"201","author":"Lindauer","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.autrev.2023.103314_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187580","article-title":"Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Martyanov","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2023.103314_bb0295","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.40934","article-title":"Senescence signature in skin biopsies from systemic sclerosis patients treated with Senolytic therapy: potential predictor of clinical response?","volume":"71","author":"Martyanov","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103314_bb0300","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","article-title":"Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis","volume":"17","author":"Chakravarty","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103314_bb0305","doi-asserted-by":"crossref","first-page":"D428","DOI":"10.1093\/nar\/gki072","article-title":"Reactome: a knowledgebase of biological pathways","volume":"33","author":"Joshi-Tope","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.autrev.2023.103314_bb0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, Placebo-Controlled Trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103314_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.933468","article-title":"Role of B-cell in the pathogenesis of systemic sclerosis","volume":"13","author":"Thoreau","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103314_bb0320","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.autrev.2015.10.005","article-title":"Systemic sclerosis: new evidence re-enforces the role of B cells","volume":"15","author":"Sakkas","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103314_bb0325","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103314_bb0330","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.106.117051","article-title":"In vitro evidence for a direct Antifibrotic role of the immunosuppressive drug mycophenolate Mofetil","volume":"321","author":"Roos","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2023.103314_bb0335","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffmann-Vold","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.autrev.2023.103314_bb0340","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2010.142000","article-title":"Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis","volume":"70","author":"Le","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2023.103314_bb0345","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European scleroderma observational study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0350","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.semarthrit.2019.06.012","article-title":"Recurrence of progressive skin involvement following discontinuation or dose reduction of mycophenolate Mofetil treatment in patients with diffuse systemic sclerosis","volume":"50","author":"Mendoza","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103314_bb0355","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate Mofetil versus Oral cyclophosphamide in scleroderma-related interstitial lung disease: scleroderma lung study II (SLS-II), a double-blind, parallel group, randomised controlled trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2023.103314_bb0360","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/annrheumdis-2021-221313","article-title":"Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease","volume":"81","author":"Assassi","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0365","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of Lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103314_bb0370","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/annrheumdis-2019-215770","article-title":"Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures","volume":"78","author":"Assassi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0375","series-title":"ACR Meeting Abstracts","article-title":"Myeloablation followed by hematopoietic stem cell transplantation leads to long-term normalization of systemic sclerosis molecular signatures","author":"Wareing","year":"2022"},{"key":"10.1016\/j.autrev.2023.103314_bb0380","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1136\/annrheumdis-2020-217033","article-title":"Machine learning predicts stem cell transplant response in severe scleroderma","volume":"79","author":"Franks","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103314_bb0385","article-title":"Clinical and molecular findings after autologous stem cell transplantation or cyclophosphamide for scleroderma: handling missing longitudinal data","author":"Keyes-Elstein","year":"2021","journal-title":"Arthritis Care Res"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:29:31Z","timestamp":1761600571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223000484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1568997223000484"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103314","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differentially expressed genes in systemic sclerosis: Towards predictive medicine with new molecular tools for clinicians","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103314"}}